

### AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### Listing of Claims

Claims 1-15 (Cancelled).

Claim 16 (Currently Amended): A method for the treatment, reduction of risk or and/or prevention of an immune system-related disorder selected from the group consisting of allergy Type 1, allergy Type 2, allergy Type 3, and allergy Type 4 in a mammal, comprising administering to said mammal a composition comprising a therapeutically effective amount of an acid oligosaccharide and a-at least two chemically distinct neutral oligosaccharide oligosaccharides, wherein:

the acid oligosaccharide has a degree of polymerization between 1 and 250 and is prepared from pectin or alginate; and

the at least two chemically distinct neutral oligosaccharide oligosaccharides comprise is selected from the group consisting of fructans, fructooligosaccharides and a second oligosaccharide selected from the group consisting of transgalactooligosaccharides, indigestible dextrins, galactooligosaccharides (including transgalactooligosaccharides), xylooligosaccharides, arabinooligosaccharides, glucooligosaccharides, mannoooligosaccharides, fucooligosaccharides and mixtures thereof.

Claims 17-19 (Cancelled).

Claim 20 (Currently Amended): The method according to claim 16, wherein the acid oligosaccharide comprises at least one terminal uronic acid unit selected from the group consisting of galacturonic acid, glucuronic acid, guluronic acid, iduronic acid, mannuronic acid, riburonic acid and alturonic acid.

Claim 21- 24 (Cancelled).

Claim 25 (Previously Presented): The method according to claim 16, wherein the composition is administered enterally.

Claim 26 (Previously Presented): The method according to claim 16, wherein the composition is administered to a human in the age of 0-1 year.

Claim 27-30 (Cancelled).

Claim 31 (Previously Presented): The method according to claim 16, wherein the immune system related disorder is allergy Type 1.

Claim 32 (Previously Presented): The method according to claim 16, wherein the immune system related disorder is a Type 1 allergy selected from the group consisting of atopy, asthma, hay fever, eczema, food allergy and drug allergy.

Claim 33 (Previously Presented): The method according to claim 32, wherein the Type 1 allergy is atopy.

Claim 34 (Previously Presented): The method according to claim 32, wherein the Type 1 allergy is eczema.

Claim 35 (Previously Presented): The method according to claim 16, further comprising administering between 0.1 and 100 g of a long-chain polyunsaturated fatty acid per day.

Claim 36 (Previously Presented): The method according to claim 16, wherein the composition further comprises an infant formula comprising between 5 and 60 en% lipid, between 5 and 40 en% protein, between 15 and 90 en% carbohydrate and long chain polyunsaturated fatty acids.

Claim 37 (Previously Presented): The method according to claim 36, wherein the infant formula comprises 7 to 12 energy% protein, 40 to 55 energy% carbohydrates and 35 to 50 energy % fat.

Claim 38 (Previously Presented): The method according to claim 36, wherein the protein is selected from the group consisting of hydrolyzed milk protein, vegetable protein and/or amino acids.

Claim 39 (Previously Presented): The method according to claim 16, wherein the composition is a liquid food which has an osmolality between 50 and 500 mOsm/kg and/or a caloric density between 0.1 and 2.5 kcal/ml.

Claim 40 (New): The method according to claim 16, wherein the method is for the treatment or reduction of risk of the immune system-related disorder.

Claim 41 (New): The method according to claim 16, wherein the immune system-related disorder is atopy in an infant.

Claim 42 (New): The method according to claim 16, wherein the method is for the treatment of the immune system-related disorder.